Investment analysts at StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research note issued on Tuesday. The brokerage set a “sell” rating on the basic materials company’s stock.
Several other research firms have also commented on RKDA. Lake Street Capital raised shares of Arcadia Biosciences to a “strong-buy” rating in a report on Tuesday, May 14th. HC Wainwright cut their target price on shares of Arcadia Biosciences from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd.
View Our Latest Stock Report on Arcadia Biosciences
Arcadia Biosciences Trading Down 0.7 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.74. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. The firm had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.20 million. During the same period in the previous year, the company earned ($3.83) earnings per share. On average, research analysts anticipate that Arcadia Biosciences will post -2.29 EPS for the current fiscal year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Stories
- Five stocks we like better than Arcadia Biosciences
- Buy P&G Now, Before It Sets A New All-Time High
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What is a Stock Market Index and How Do You Use Them?
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.